LEADER 02334oam 2200625I 450 001 9910707446903321 005 20160831144226.0 035 $a(CKB)5470000002465060 035 $a(OCoLC)885121039 035 $a(EXLCZ)995470000002465060 100 $a20140802d1959 ua 0 101 0 $aeng 135 $aurn|||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aLead-alpha age determinations of accessory minerals of igneous rocks (1953-1957) /$fby Howard W. Jaffe, Claude L. Waring, and Helen W. Worthing 210 1$aWashington, D.C. :$cUnited States Department of the Interior, Geological Survey,$d1959. 210 2$aWashington, D.C. :$cGovernment Printing Office. 215 $a1 online resource (iii, 65-148 pages) $ccharts 225 1 $aGeological Survey bulletin ;$v1097-B 300 $a"This report concerns work done in part on behalf of the U. S. Atomic Energy Commisionand is published with the permission of the Commission." 300 $aTitle from title screen (viewed July 23, 2014). 320 $aIncludes bibliographical references (pages 145-148). 517 $aLead-alpha age determinations of accessory minerals of igneous rocks 606 $aGeological time 606 $aIgneous rocks 606 $aOres$xSampling and estimation 606 $aRadioactive prospecting 606 $aGeological time$2fast 606 $aIgneous rocks$2fast 606 $aOres$xSampling and estimation$2fast 606 $aRadioactive prospecting$2fast 615 0$aGeological time. 615 0$aIgneous rocks. 615 0$aOres$xSampling and estimation. 615 0$aRadioactive prospecting. 615 7$aGeological time. 615 7$aIgneous rocks. 615 7$aOres$xSampling and estimation. 615 7$aRadioactive prospecting. 700 $aJaffe$b Howard W.$01414318 702 $aWaring$b C. L$g(Claude L.), 702 $aWorthing$b Helen W. 712 02$aGeological Survey (U.S.), 712 02$aU.S. Atomic Energy Commission, 801 0$bCOP 801 1$bCOP 801 2$bOCLCO 801 2$bOCLCF 801 2$bGPO 906 $aBOOK 912 $a9910707446903321 996 $aLead-alpha age determinations of accessory minerals of igneous rocks (1953-1957)$93513231 997 $aUNINA LEADER 04205nam 22007815 450 001 9910300177003321 005 20250609111625.0 010 $a3-319-22714-9 024 7 $a10.1007/978-3-319-22714-6 035 $a(CKB)3710000000492397 035 $a(EBL)4178505 035 $a(SSID)ssj0001584819 035 $a(PQKBManifestationID)16265135 035 $a(PQKBTitleCode)TC0001584819 035 $a(PQKBWorkID)14864288 035 $a(PQKB)10150367 035 $a(DE-He213)978-3-319-22714-6 035 $a(MiAaPQ)EBC4178505 035 $a(PPN)190525894 035 $a(MiAaPQ)EBC6241767 035 $a(EXLCZ)993710000000492397 100 $a20151012d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAgammaglobulinemia /$fedited by Alessandro Plebani, Vassilios Lougaris 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (126 p.) 225 1 $aRare Diseases of the Immune System,$x2282-6505 ;$v4 300 $aDescription based upon print version of record. 311 08$a3-319-22713-0 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aEarly B Cell Biology -- Agammaglobulinemia: Basic Pathogenesis and Clinical Spectrum (Including X-Linked and Autosomal Recessive Forms) -- Pulmonary Complications in Agammaglobulinemia -- Immunoglobulin Replacement Therapy: Past, Present, Future -- Mutational Spectrum of BTK: A Comprehensive Description -- Novel Therapeutic Options for X-Linked Agammaglobulinemia -- BTK in Non B Cells. 330 $aThis book provides an updated overview of agammaglobulinemia, a rare form of primary immunodeficiency which is considered the prototype of the congenital humoral defects, and which is characterized by the absence of peripheral B cells and very low serum immunoglobulin levels. The book opens by discussing the highly orchestrated early B cell development in the bone marrow and the genes involved based on both human and animal models. The pathogenesis and clinical presentation of X-linked agammaglobulinemia, caused by mutations in the BTK (Bruton?s tyrosine kinase) gene, are then presented in detail, followed by descriptions of the clinical manifestations and molecular basis of the less frequent autosomal recessive and autosomal dominant forms of agammaglobulinemia.  Patients? management in terms of respiratory complications, gammaglobulin replacement therapy and the potential value of novel experimental therapeutic strategies are  discussed. The book?s closing chapters offer a comprehensive and updated description of mutations in the BTK gene, and the expression and function of BTK in cells other than B cells. 410 0$aRare Diseases of the Immune System,$x2282-6505 ;$v4 606 $aImmunology 606 $aRheumatology 606 $aHematology 606 $aPediatrics 606 $aCytology 606 $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000 606 $aRheumatology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33170 606 $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X 606 $aPediatrics$3https://scigraph.springernature.com/ontologies/product-market-codes/H49006 606 $aCell Biology$3https://scigraph.springernature.com/ontologies/product-market-codes/L16008 615 0$aImmunology. 615 0$aRheumatology. 615 0$aHematology. 615 0$aPediatrics. 615 0$aCytology. 615 14$aImmunology. 615 24$aRheumatology. 615 24$aHematology. 615 24$aPediatrics. 615 24$aCell Biology. 676 $a616.0798 702 $aPlebani$b Alessandro$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aLougaris$b Vassilios$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910300177003321 996 $aAgammaglobulinemia$91759370 997 $aUNINA